Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(33%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_2
4
67%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(4)

Detailed Status

Completed4
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

recruiting233%
completed467%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077
completedphase_2

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

NCT05050149
completedphase_2

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486
completedphase_2

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

NCT03920228
completedphase_3

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

NCT04520750
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07552077Phase 2

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Recruiting
NCT05050149Phase 2

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Completed
NCT04893486Phase 2

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Completed
NCT03920228Phase 2

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Completed
NCT04520750Phase 3

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Completed
NCT05643872Phase 3

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6